What it’s about
The Advanced Fat Loss Stack is the maximum configuration for metabolic research. At the center stands Retatrutide as a triple co-agonist with the broadest receptor coverage of the GLP-1 family, complemented by Cagrilintide for the amylin axis and AOD-9604 for direct lipolysis.
In contrast to the Cut Stack with a Tirzepatide anchor, this configuration uses the most potent GLP compound available. The complementary compounds continue to address axes that Retatrutide does not directly cover, keeping the three-axis logic mechanistically clean.
The Compounds
Retatrutide is a triple co-agonist at GLP-1, GIP and glucagon receptors. In preclinical studies, the compound is associated with the broadest mechanism coverage of modern GLP research. The additional glucagon component extends beyond the Tirzepatide axis to central metabolic pathways in the liver and tissue metabolism.
Cagrilintide is an amylin analog and mechanistically independent of the GLP family. Even with a Retatrutide anchor, the amylin pathway remains a separate satiety axis not covered by GLP-1, GIP or glucagon receptors.
AOD-9604 addresses peripheral adipocyte lipolysis via an HGH-derived pathway. Completely independent of the central GLP axis and the amylin axis. Extends the stack with direct action at adipose tissue.
Research Context
Retatrutide represents the current state of GLP research with triple receptor architecture. The glucagon component distinguishes it substantially from Tirzepatide because it triggers signals counter to insulin in the liver and thus addresses additional metabolic pathways. In preclinical studies, Retatrutide is frequently characterized solo since the multiple receptor activation is already extensive. Cagrilintide and AOD-9604 complement axes outside the GLP family, avoiding receptor overlap.
This information is for research and educational purposes only. No medical recommendations.